EpiSwitch® CIRT Response Test Requisition Form

To order the test, fax the completed requisition form to 1.240.913.5681. For any questions, please call 1.888.236.8896 or email CiRT.TEST@myOBDX.com

For Lab Use

Order #

For Lab Use

Kit Barcode ID #

Patient Information								
					Month	Day	Year	Gender: (optio
irst Name	MI Last N	lame	Medica	Record # (option		Buy		F N
Address		City	State	Postal Code	Country		Primary Pho	one
				i ootai ooao	oodiniiy			5110
Patient Diagnosis & History								
rimary ICD-10 (C&D codes only)			Diagnos	is				
Additional Case information (optior	nal)							
reating Physician Informat	ion			Pl	ease provide be	st contact i	nformation fo	r case follow-u
acility or Practice Name		Treating	Physician (full legal i	name)			NPI Numbe	r
acility/Practice Address		City		State	Postal Code		Country	
		,					,	
Oxford BioDynamics Account # (optic	onal)	Email (optional)			Phone		Fax	
Additional Physician to be Copied (or	otional)	Facility Name (optional)	Er	nail (optional)			Fax (option	al)
est Menu and Specimen Co		, , ,					× 1	•
					A a a a rate of Grad		1 din inc	Values Bassin
Test	Description				Accepted Spe	лпен туре		Volume Requir
EpiSwitch CiRT Response Test		t that identifies a cancer patie hhibitor (Blockade) Therapy.	ent's likely response t	o an Immune	Whole blood, EDT	A Tube	3 mL	
lonth Day Year				Month	Day Year	0		
pecimen Collection Date		re/Medicaid patients: llected during a hospital inpat	tient period? Yes	No Hospital disc	,	·	men collected d tal outpatient er	-
ntended Use and Technical	Informatio	n						
				structures in the im		ss the likelihoo	d of rosponso to	immuna chackna
ntended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A	oonse Test (CiRT Atezolizumab, Av) is a blood test that evaluates elumab, Duralumab) and PD-1	1 (Pembrolizumab). Th	e results are not sp	pecific to ICI agent	or to type of t		
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre	ponse Test (CiRT Atezolizumab, Av eatment profess) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic	l (Pembrolizumab). Th cture. It should not be	e results are not sp used as the sole do	pecific to ICI agent ata point in treatme	or to type of t nt decisions.	umor. The test is	intended to provi
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre piSwitch CiRT Response Test is a lab aboratory Improvement Amendments	ponse Test (CiRT Atezolizumab, Av patment profess poratory develo s (CLIA) to perfo) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sir	intended to provi ed under the Clini ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre oiswitch CiRT Response Test is a lab aboratory Improvement Amendments est, rather, on the independent medic	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking ir	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sir	intended to provi ed under the Clini ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (<i>A</i> upplemental information to cancer tre biswitch CIRT Response Test is a lab aboratory Improvement Amendments ist, rather, on the independent medic accordance with the standard of care	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking ir	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sir	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (<i>A</i> upplemental information to cancer tre biSwitch CIRT Response Test is a lab aboratory Improvement Amendments ust, rather, on the independent medic accordance with the standard of care	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking ir	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sir	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre piswitch CiRT Response Test is a lab aboratory Improvement Amendments est, rather, on the independent medic ccordance with the standard of care Billing Information	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking ir	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sir	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre oiswitch CiRT Response Test is a lab aboratory Improvement Amendments est, rather, on the independent medic ccordance with the standard of care Billing Information	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic bed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t ent decisions. ation. The labe ald not be sole	umor. The test is pratory is certific ly based on a sin itions, including o	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-LI (A upplemental information to cancer tre biSwitch CiRT Response Test is a lab aboratory Improvement Amendments st, rather, on the independent medic ccordance with the standard of care Billing Information	ponse Test (CiRT Mezolizumab, Av eatment profess poratory develo s (CLIA) to perfo al judgment of f) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic bed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	l (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	pecific to ICI agent ata point in treatme nd Drug Administr and treatment shou	or to type of t int decisions. ation. The labe ald not be sole batient's cond	umor. The test is pratory is certific ly based on a sin itions, including o	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre biSwitch CiRT Response Test is a lab aboratory Improvement Amendments ust, rather, on the independent medic coordance with the standard of care Billing Information	conse Test (CiRT htezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of f in each healthd) is a blood test that evaluates elumab, Duralumab) and PD- ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting. Email	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	becific to ICI agent ata point in treatmen nd Drug Administri and treatment shou on concerning the p State Postal C	or to type of t int decisions. ation. The lab- ild not be sole batient's cond	umor. The test is pratory is certifie ly based on a si itions, including of Phone	intended to provi ed under the Clinic ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre biSwitch CiRT Response Test is a lab aboratory Improvement Amendments ist, rather, on the independent medic coordance with the standard of care Billing Information	conse Test (CiRT htezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of f in each healthd) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic bed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting. Email City	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	becific to ICI agent ata point in treatmen nd Drug Administri and treatment shou on concerning the p State Postal C	or to type of t int decisions. ation. The lab- ild not be sole batient's cond	umor. The test is pratory is certifie ly based on a si itions, including of Phone	intended to provi ed under the Clini ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-L1 (A upplemental information to cancer tre biSwitch CiRT Response Test is a lab aboratory Improvement Amendments ist, rather, on the independent medic coordance with the standard of care Billing Information Contact Name	ponse Test (CiRT Itezolizumab, Av aatment profess ooratory develoj s (CLIA) to perfo al judgment of f in each healthd) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting. Email City ents, attach Patient Agreement	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	State Postal C Card Authorizatio	or to type of t int decisions. ation. The lab- ild not be sole batient's cond	umor. The test is pratory is certifie ly based on a si itions, including of Phone	intended to provi ed under the Clini ngle test such as t
tended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-LI (A applemental information to cancer tre biSwitch CiRT Response Test is a lab aboratory Improvement Amendments st, rather, on the independent medic coordance with the standard of care Billing Information Contact Name Address Insurance Self-pay (For Insurance Carrier Attach copies of in	oonse Test (CiRT titezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of f in each healtho or self-pay pati) is a blood test that evaluates elumab, Duralumab) and PD- ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	State Postal C Card Authorizatio	or to type of t int decisions. ation. The labe ald not be sole boatient's cond	umor. The test is pratory is certifie ly based on a si itions, including of Phone Country	intended to provi ad under the Clinic gle test such as t other clinical tests
Andress Address Addres	oonse Test (CiRT titezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of f in each healtho or self-pay pati) is a blood test that evaluates elumab, Duralumab) and PD- ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d	e results are not sp used as the sole do by the US Food a ding patient care o vailable informatio	State Postal C Card Authorizatio	or to type of t int decisions. ation. The labe ald not be sole boatient's cond	umor. The test is pratory is certifie ly based on a si itions, including of Phone Country	intended to provi ad under the Clinic gle test such as t other clinical tests
Intended Use and Technical Intended Use: Checkpoint inhibitor Resp inhibitor (ICI) therapy targeting PD-LI (A upplemental information to cancer tree piswitch CiRT Response Test is a lab aboratory Improvement Amendments est, rather, on the independent medic laccordance with the standard of care Billing Information Contact Name Address Insurance Self-pay (Fa Insurance Carrier Attach copies of a Test Authorization and Physe The undersigned certifies that he/she is	oonse Test (CiRT htezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of 1 in each healtho or self-pay pati insurance card sician Signa) is a blood test that evaluates elumab, Duralumab) and PD- ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d nt of Financial Respon	e results are not sp used as the sole do by the US Food a ding patient care of vailable information maintenance ma	State Postal C Card Authorization	or to type of tr nt decisions. ation. The lab ild not be sole batient's cond ode n form.) Spouse	umor. The test is pratory is certifie ly based on a si itions, including of Phone Country	intended to provi
Attended Use: Checkpoint inhibitor Resp hibitor (ICI) therapy targeting PD-LI (A upplemental information to cancer tre piSwitch CiRT Response Test is a lab aboratory Improvement Amendments est, rather, on the independent medic accordance with the standard of care Billing Information Contact Name Address nsurance Self-pay (For nsurance Carrier Attach copies of a Test Authorization and Phys	oonse Test (CiRT htezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of 1 in each healtho or self-pay pati insurance card sician Signa) is a blood test that evaluates elumab, Duralumab) and PD- ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting.	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d nt of Financial Respon	e results are not sp used as the sole do by the US Food a ding patient care of vailable information maintenance ma	State Postal C Card Authorization	or to type of t int decisions. ation. The lab- ild not be sole batient's cond ode n form.) Spouse of this patient.	umor. The test is pratory is certifie ly based on a sir litions, including of Phone Country Child	a intended to provi ad under the Clinic ngle test such as to other clinical tests
Andress Address Addres	oonse Test (CiRT htezolizumab, Av patment profess poratory develo s (CLIA) to perfo al judgment of 1 in each healtho or self-pay pati insurance card sician Signa) is a blood test that evaluates elumab, Duralumab) and PD-1 ionals on the overall clinical pic oed test (LDT). It has not beer rm high-complexity clinical te the treating physician taking in care setting. Email City ents, attach Patient Agreement (s), front and back. ture er the test(s) listed above and th	I (Pembrolizumab). Th cture. It should not be n reviewed or cleared sting. Decisions regar nto consideration all d nt of Financial Respon	e results are not sp used as the sole do by the US Food a ding patient care of vailable information maintenance ma	State Postal C Card Authorization	or to type of t int decisions. ation. The lab- ild not be sole batient's cond ode n form.) Spouse of this patient.	umor. The test is pratory is certifie ly based on a si itions, including of Phone Country	intended to provi

EpiSwitch® CiRT *is the only test* that predicts how a patient will respond to immune checkpoint inhibitor (ICI) therapies



Order the CiRT test

The Checkpoint inhibitor Response Test (CiRT) can only be ordered by a physician using the CiRT Requisition Form

Download the <u>Requisition Form</u> at <u>https://myCiRT.co/order-test</u>



Complete the Requisition Form

Work with your physician to complete the **<u>Requisition Form</u>**

• Your physician will fax the completed form to +1 240-913-5681



Provide a small blood sample

- CiRT Customer Service will send you or your physician a Specimen Submission Kit to ship your blood sample
- Coordinate with your provider to schedule a blood draw



Receive your CiRT test result

Within 5 days of receiving the sample, your Checkpoint inhibitor Response Report will be sent to your physician

• Navigate the toughest challenges of immunotherapy by knowing your likelihood of response to ICI therapy

Questions? Email CiRT Customer Service at CiRT.test@myOBDX.com



Learn more at www.myCiRT.com

